| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to compounds of general formula I–IV possessing property of enzyme inhibitor PRMT5, their application, pharmaceutical composition based on them, method of treating abnormal growth of cells, including various types of cancer. In general formula I Ris selected from a group comprising (C-C)alkyl and N(R), where each Rindependently is A-R, where A is absent and Ris hydrogen; Ris hydrogen, (C-C)alkyl or N(R), where each Rindependently is hydrogen; each Rare independently selected from hydrogen, hydroxy, (C-C)alkyl, or if D is C(R), Radditionally selected from fluorine; each Rindependently is hydrogen; D is C(R), O; G is phenyl or 10–12-member heteroaryl ring system with 1 to 2 nitrogen atoms or 9–11-heterocyclic ring system with 1 to 2 heteroatoms selected from nitrogen and oxygen; each Ris absent or is independently selected from a group comprising (C-C)alkyl, (C-C)haloalkyl, hydroxy, (C-C)alkoxy, 5-member heteroaryl with 2-3 heteroatoms selected from N, O and S, CN, halogen and CON(R), and where two Roptionally combined with formation of carbonate; Q is absent; V is N or C, if Z is present, where if V forms a double bond, V is carbon or V is N or CH and forms a double bond with W, if Z is absent; W is C, where if W forms a double bond, if W is carbon; X is N, if Y is present, where if X forms a double bond, X is carbon or X is NR, if Y is absent, where Ris H or methyl; Y is absent, is CR; Z is absent, is CR, where each Rindependently selected from hydrogen, fluorine, chlorine, bromine.EFFECT: substituted carbonucleosides derivatives used as anticancer agents are disclosed.39 cl, 2 tbl, 216 ex |